NEW YORK (GenomeWeb) – With the US Food and Drug Administration's approval for AstraZeneca's Iressa (gefitinib), metastatic non-small cell lung cancer patients whose tumors have EGFR mutations now have three personalized treatment options.
Importantly for the drug giant, which has been out of the US lung cancer market for a decade, the approval also may serve as a launch pad for it to re-establish its presence with next generation and combination products.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.